Xeris Biopharma Holdings (XERS) Receivables (2020 - 2026)
Xeris Biopharma Holdings' (XERS) quarterly Receivables came in at $56.3 million in Q1 2026, up 21.51% YoY from $46.3 million in Q1 2025, and up 10.27% on a QoQ basis from $51.0 million in Q4 2025.
Xeris Biopharma Holdings (XERS) Receivables (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings (XERS) has 7 years of Receivables data on file, last reported at $56.3 million in Q1 2026.
- Quarterly Receivables rose 21.51% year-over-year to $56.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $56.3 million (up 21.51% YoY) and the FY2025 annual result came in at $51.0 million, up 26.31% from the prior year.
- Receivables improved to $56.3 million in Q1 2026, from $51.0 million in the prior quarter.
- In the past five years, Receivables ranged from a high of $56.3 million in Q1 2026 to a low of $23.4 million in Q1 2022.
- A 5-year average of $39.7 million and a median of $40.4 million in 2024 frame the typical range for Receivables.
- Annual changes were most pronounced in 2022 — Receivables surged 102.92% — and 2024, when it dropped 10.5%.
- Tracing XERS's Receivables over 5 years: stood at $30.8 million in 2022, then increased by 27.14% to $39.2 million in 2023, then rose by 3.11% to $40.4 million in 2024, then rose by 26.31% to $51.0 million in 2025, then grew by 10.27% to $56.3 million in 2026.
- The last three Receivables figures came in at $56.3 million (Q1 2026), $51.0 million (Q4 2025), and $53.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 3.07 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 3.49 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 1.57 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 5.84 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 310.30 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 3.67 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 887.00 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 1.15 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 1.08 Bn |
| 10 | Xeris Biopharma Holdings | 1.48 Bn | 1.36 Bn | 79.59 Mn | 58.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 58.11 Mn |
| Mar 31, 2026 | 56.30 Mn |
| Dec 31, 2025 | 51.05 Mn |
| Sep 30, 2025 | 53.75 Mn |
| Jun 30, 2025 | 53.05 Mn |
| Mar 31, 2025 | 46.33 Mn |
| Dec 31, 2024 | 40.42 Mn |
| Sep 30, 2024 | 41.14 Mn |
| Jun 30, 2024 | 42.44 Mn |
| Mar 31, 2024 | 37.41 Mn |
| Dec 31, 2023 | 39.20 Mn |
| Sep 30, 2023 | 45.97 Mn |
| Jun 30, 2023 | 30.23 Mn |
| Mar 31, 2023 | 30.86 Mn |
| Dec 31, 2022 | 30.83 Mn |
| Sep 30, 2022 | 27.52 Mn |
| Jun 30, 2022 | 25.76 Mn |
| Mar 31, 2022 | 23.38 Mn |
| Dec 31, 2021 | 17.46 Mn |
| Sep 30, 2021 | 13.56 Mn |